AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03914729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Closure
Description: A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
Study NCT03914729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gluteus Maximus Fascia Plasty Flap
Description: A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
Study NCT01365832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
Study NCT02105584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of LAA closure device
Study NCT03857074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Light Exposure
Description: To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
Study NCT00758277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam (Keppra)
Description: levetiracetam daily application 1500-2000 mg
Study NCT00758277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study NCT02215382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex 2 mg/kg
Study NCT02215382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine+atropine
Description: neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
Study NCT01771640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: Intrathecal injection of mesenchymal stem cells in patients with ALS
Study NCT04193124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transcranial doppler.
Description: Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
Study NCT02864394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered IV at 2 mg/kg on Day 1 of each 21-day cycle for up to 35 doses (approximately 24 months).
Study NCT02864394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered IV at 75 mg/m\^2 on Day 1 of each 21-day cycle as per the approved product label.
Study NCT00921596 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac operation with totally endoscopic method
Description: Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
Study NCT05742022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phospholipovit
Description: 500 mg orally 2 times a day, for 12 weeks
Study NCT05742022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 500 mg orally 2 times a day, for 12 weeks
Study NCT00081497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: agalsidase beta
Description: 1.0 mg/kg every 2 weeks
Study NCT03409796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gluten
Description: Gluten powder.
Study NCT00727467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Cueing Device
Description: Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
Study NCT00727467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auditory Cueing Device
Description: Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
Study NCT02044354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Taxotere
Study NCT02044354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Jevtana
Study NCT01638455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive device
Description: Noninvasive device
Study NCT03306914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Albumin resuscitation
Description: Albumin 5% is used as the intra-operative colloid
Study NCT03306914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch resuscitation
Description: Hydroxyethyl starch 6% is used as the intra-operative colloid
Study NCT03306914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 5%
Description: Infusion of Albumin 5% intra-operatively
Study NCT03306914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6%
Description: Infusion of Hydroxyethylstarch 6% intra-operatively
Study NCT01212835 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: no ring
Description: Open roux-en-Y gastric bypass not banded
Study NCT01212835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGBP-RING
Description: Vertical Roux-en-Y banded gastric bypass
Study NCT03084211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light exercise discharge instructions
Description: Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
Study NCT01112826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 650 mg/m2 twice every day for 1 year.
Study NCT03422913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: controlled low central venous pressure
Description: Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0\~5cm H2O, if CVP is still >5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) > 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 \~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
Study NCT00907595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Study NCT00907595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
Study NCT01769742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early mobility bundle
Study NCT03641417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01
Description: Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)
Study NCT03641417 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as GLWL-01, but no active ingredient
Study NCT05974241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate, aripiprazole, and combination
Description: Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
Study NCT01544296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6188
Study NCT01544296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01873937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Red LED
Description: Phototherapy with red LED on temporomandibular area
Study NCT01873937 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: INFRARED LED
Description: Phototherapy with infrared LED on temporomandibular area
Study NCT01873937 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: Phototherapy with LASER INFRARED on temporomandibular area
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old
Description: freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT02288286 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old
Description: freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
Study NCT04391374 — intervention group
Intervention type: PROCEDURE
Intervention: an arterial reconstructive procedure
Study NCT00836368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gamma-tocopherol
Description: oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
Study NCT00966654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
Study NCT00966654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 (7-36) amide
Description: 1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
Study NCT03684616 — intervention group
Intervention type: DRUG
Intervention: Statin
Description: continuous statin treatment for 3 months prior to cardiac arrest
Study NCT03400735 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir/clavulanic acide 300/125 mg film-coated tablets
Description: Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
Study NCT03400735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300Mg Capsule
Description: Cefdinir is used as comparator
Study NCT03612817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost/timolol fixed combination
Description: Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
Study NCT03737695 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo biospecimen collection
Study NCT03737695 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo clinical information collection
Study NCT04441905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One time 60-minute IV infusion of lyophilized placebo for SAR440894
Study NCT04441905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR440894
Description: One time 60-minute IV infusion of SAR440894 monoclonal antibody (IgG1) directed against the E2 envelope protein of chikungunya virus
Study NCT03742076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-dose prebiotic
Description: This is a spray-dried powder, yellowish-white in color, that is dissolvable.
Study NCT03742076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose prebiotic
Description: This is a spray-dried powder, yellowish-white in color, that is dissolvable.
Study NCT03742076 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder fiber supplement, yellowish-white in color, that is dissolvable.
Study NCT00972413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
Study NCT00972413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
Study NCT00972413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
Study NCT00582439 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reamer-Irrigator-Aspirator (RIA)
Description: Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
Study NCT01992796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: 75 mg/per os/for 15 days
Study NCT03415321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postpartum Mobile Support Application
Description: Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use
Study NCT00139152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline, Sub-Cuteanous (SQ)
Study NCT00139152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
Study NCT04355754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventil - a gas flow divider
Description: Checking ventilation parameters set and obtained and clinical parameters while ventilating the patient and an artificial lung simultaneously, using inspiratory flow divider.
Study NCT01866332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
Study NCT01866332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
Study NCT01866332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tex Gold ( Kinesiotaping )
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
Study NCT04515771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER-MH
Description: The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
Study NCT04515771 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PARTNER-MH
Description: The study intervention consisted of a 6-month, manualized, peer-led navigation program. It involved assessing and addressing patients' unmet social needs and barriers to care, delivery of peer support services, navigation to VA mental health services, and psychoeducation.
Study NCT03261648 — intervention group
Intervention type: OTHER
Intervention: State-Trait-Anxiety Inventory (Forme Y) questionnaire
Description: after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
Study NCT03261648 — intervention group
Intervention type: OTHER
Intervention: pain level scale
Description: as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
Study NCT00948246 — intervention group
Intervention type: DEVICE
Intervention: Easyband®
Description: The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
Study NCT02764385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teachable Moment Communication Process
Description: A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
Study NCT02764385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AAC
Description: A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
Study NCT04291547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BALM
Description: An online Behavioural Activation programme for young people with mild to moderate low mood/depression. The programme comprises 10 treatment sessions lasting 30 to 45 minutes
Study NCT00445081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT00445081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporine A
Study NCT03664531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Purified gluten
Description: 1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
Study NCT03664531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-purified gluten (containing ATIs)
Description: 1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.